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INTRODUCTION
Terbinafine is a member of allylamine class of antifungal
agents, which have been used effectively to treat dermato-
mycoses (1). Although it generally has been well tolerated,
several cases of generalized pustular psoriasis (GPP) after oral
terbinafine therapy have been reported. However, in no report
has hepatic dysfunction been associated with a GPP after
terbinafine therapy. Herein, we report a case of terbinafine
induced GPP with an elevation in his liver function tests,
and to the best of our knowledge, this is the first in literature.
CASE REPORT
A 61-yr-old man with 5-yr history of stable psoriasis was
admitted to our hospital for generalized erythroderma and
micropustular eruption. He had been treated elsewhere for
clinically diagnosed onychomycosis with terbinafine 250 mg
daily and had discontinued therapy after 4 days of treatment
due to such events. Patient did not recognize of any other
drug history within 2 months, nor had any history of liver
disease. There was no family history of psoriasis and the pati-
ent was not on medication for psoriasis since it had remained
stable in recent 1 yr.
On admission, the patient revealed widespread erythema
and multiple tiny pustules were studded on neck, trunk and
both extremities (Fig. 1). The patient had a fever of 39.1℃
and complained of constitutional symptoms of general weak-
ness, arthralgia and myalgia. The white cell count was 24.09
×109/L with marked neutrophilia. Baseline liver function
studies performed prior to administration of terbinafine were
within normal range. Cultures for bacteria and fungi from
the pustules did not reveal any organism. Skin biopsy revealed
psoriasiform acanthosis and subcorneal spongiform pustules
filled with neutrophils (Fig. 2). There was sparse exocytosis
of eosinophils, and superficial dermal edema was not promi-
nent. Neither necrotic keratinocytes nor signs of vasculitis
were present. The histopathological findings were consistent
with clinical diagnosis of pustular psoriasis rather than acute
generalized exanthematous pustulosis (AGEP). Liver func-
tion studies after 4 days of admission revealed SGOT 219
IU/L (normal range <40 IU/L), SGPT 376 IU/L (<44 IU/L),
and alkaline phosphatase 564 IU/L (95-280 IU/L), while
blood serology excluded viral hepatitis. Therapy during the
admission consisted of topical corticosteroid and calcipotriol
combination with narrow band ultraviolet B. After 2 weeks of
treatment, there was near complete resolution of the skin erup-
tion and elevated liver enzymes returned to normal. He remains
well and free of any pustular eruptions 18 months later and
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Generalized Pustular Psoriasis and Hepatic Dysfunction Associated
with Oral Terbinafine Therapy 
We report a case of 61-yr-old man with stable psoriasis who progressively devel-
oped generalized pustular eruption, erythroderma, fever, and hepatic dysfunction
following oral terbinafine. Skin biopsy was compatible with pustular psoriasis. After
discontinuation of terbinafine and initiating topical corticosteroid and calcipotriol com-
bination with narrow band ultraviolet B therapy, patient’s condition slowly improved
until complete remission was reached 2 weeks later. The diagnosis of generalized
pustular psoriasis (GPP) induced by oral terbinafine was made. To our knowledge,
this is the first report of GPP accompanied by hepatic dysfunction associated with
oral terbinafine therapy. 
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DISCUSSION
Adverse effects have been reported in 10.5% of patients
receiving oral terbinafine (1). Common cutaneous adverse
reactions are rash, pruritus, urticaria, and eczema (1). Less
common but more significant or life-threatening cutaneous
reactions include acute generalized exanthematous pustulo-
sis, erythema multiforme, Stevens-Johnson syndrome, toxic
epidermal necrolysis, exacerbation or induction of psoriasis
and erythroderma (2-9). Hepatobiliary toxicity has been
reported much infrequently in 0.2% (1).
Pustular eruptions associated with terbinafine have rarely
been reported in literature. To our knowledge, there are 11
cases of AGEP and 4 cases of GPP induced by terbinafine
(Table 1). Among those reports of GPP, only 1 case was exac-
erbating from pre-existing psoriasis and we could not find
any documented case accompanying with significant hepat-
ic involvements.
GPP and AGEP are uncommon condition characterized
by generalized sterile micropustular eruption. However, GPP
clinically and histologically may be difficult to distinguish
from AGEP. Moreover, if GPP has a history of preceding
drug exposure, the differentiation may be much more chal-
lenging (10). Although there have been no clear-cut rules,
some studies described peculiar characteristics that may jus-
tify the distinction. Roujeau et al. (11) described that AGEP
usually shows massive edema in the superficial dermis, vas-
culitis, exocytosis of eosinophils, and single-cell necrosis of
keratinocytes, while pustular psoriasis shows papilloacantho-
sis. Spencer et al. (10) cited that the absence of a personal or
family history of psoriasis, rapid resoluton after withdrawal of
the offending agents, the presence of a variable numbers of
eosinophil infiltrations, and absence of psoriasiform histo-
logic features; all suggest of pustular drug eruptions (AGEP).
In present case, patient’s past history of stable psoriasis and
typical histological feature of psoriasis strongly suggest of
pustular psoriasis rather than AGEP. Histologically not con-
taining eosinophils in his biopsy specimen also favored the
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Fig. 1. (A) Generalized erythema covered with tiny pustules and scalings. (B) Close-up view of pustules on erythematous background. 
A B
Fig. 2. Subcorneal spongiform pustules with psoriasiform hyper-
plasia (hematoxylin-eosion stain, ×40).diagnosis. Because of widespread desquamative and pustular
erythroderma associated with fever and altered general con-
ditions, this case is considered pustular psoriasis of the von
Zumbusch type.
In conclusion, our case suggests that oral terbinafine can
provoke GPP concomitantly with hepatic involvement, and
therefore physicians should carefully monitor hepatic enzymes
when serious cutaneous adverse events occur during the use
of terbinafine.
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Wilson and   M/65 2 weeks - Widespread  39 Consistent with pustular psoriasis 29,500 NP Acitretin NM
Evans (9) pustular eruption
Gupta et al. (8) M/50 27 days - Generalized pustules  NM Acanthosis and collection of 17,000 NM Topical and   16 weeks
and erythroderma neutrophils within stratum corneum, systemic
focal absence of granular layer, steroids,
spongiosis, exocytosis of neutrophils, methotrexate
perivascular inflammatory cell 
infiltration including eosinophils
Gupta et al. (8) F/54 21 days + Generalized pustules  38.1 Psoriasiform acanthosis, absence 19,000 NM Topical  2 weeks
and erythroderma of granular layer, spongiform  steroids
pustules filled with neutrophils,
perivascular lymphocytic infiltrations
Wach et al. (12) F/56 5 days - Widespread EAC-like NM NM NM NM Systemic 2 weeks
psoriatic eruptions,  steroids
single pustular lesions 
on her extremities & trunk
Present case M/61 4 days + Generalized pustules  39.1 Parakeratosis, psoriasiform  24,000 + Topical  2 weeks
and erythroderma acanthosis, spongiform pustules steroids, topical 
filled with neutrophils, perivascular calcipotriol,
lymphocytic infiltrations NB-UVB
Table 1. Reported cases of generalized pustular psoriasis induced by terbinafine
M, male; F, female; NM, not mentioned; NP, not prominent; EAC, erythema annulare centrifugum; NB-UVB, narrow band UVB.